Sector Gamma AS Sells 10,000 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Sector Gamma AS reduced its stake in BioNTech SE by 25.0%, now holding 30,000 shares valued at approximately $2.73 million, making it the company's 27th largest holding.
• BioNTech reported a loss of $1.60 per share for the recent quarter, missing expectations, but showed a 102.6% year-over-year revenue increase with revenues hitting $306.46 million.
• Analysts have a consensus rating of "Moderate Buy" for BioNTech, with a target price average of $135.80.

Sector Gamma AS decreased its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 25.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,000 shares of the company's stock after selling 10,000 shares during the period. BioNTech makes up 0.9% of Sector Gamma AS's investment portfolio, making the stock its 27th largest holding. Sector Gamma AS's holdings in BioNTech were worth $2,732,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of BNTX. Geode Capital Management LLC boosted its stake in shares of BioNTech by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 101,715 shares of the company's stock valued at $11,590,000 after purchasing an additional 1,063 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of BioNTech during the 4th quarter valued at about $584,000. Bridgewater Associates LP boosted its stake in shares of BioNTech by 257.4% during the 4th quarter. Bridgewater Associates LP now owns 20,277 shares of the company's stock valued at $2,311,000 after purchasing an additional 14,604 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of BioNTech by 32.9% during the 4th quarter. Marshall Wace LLP now owns 150,157 shares of the company's stock valued at $17,108,000 after purchasing an additional 37,177 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its position in BioNTech by 63.5% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,791 shares of the company's stock valued at $887,000 after buying an additional 3,025 shares during the period. Institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. HC Wainwright lowered their price objective on BioNTech from $138.00 to $136.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Morgan Stanley raised their price objective on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Citigroup reaffirmed a "buy" rating and set a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group started coverage on BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. Thirteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $135.80.

BioNTech Stock Down 0.1%

Shares of NASDAQ:BNTX traded down $0.10 during trading on Wednesday, reaching $111.30. 1,006,734 shares of the stock traded hands, compared to its average volume of 671,303. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The stock has a market cap of $26.76 billion, a P/E ratio of -69.56 and a beta of 1.23. The stock has a 50-day moving average of $109.70 and a two-hundred day moving average of $105.70. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech's revenue was up 102.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.